How has the rare biomarkers specimen collection and stabilization market evolved, and where is it heading next?
The rare biomarkers specimen collection and stabilization market size has grown rapidly in recent years. It will grow from $32.01 billion in 2024 to $35.4 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to the human genome project, increase in cancer research, pharmaceutical R&D investment, growth of genomics and proteomics, and improved data management and bioinformatics.
The rare biomarkers specimen collection and stabilization market size is expected to see rapid growth in the next few years. It will grow to $52.46 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to the expansion of liquid biopsy applications, consumer awareness and demand, increasing adoption of non-invasive techniques, and biomarker discovery in rare diseases. Major trends in the forecast period include advancements in preservation technology, growth in genomic and proteomic research, the emergence of point-of-care testing, and regulatory advancements and standardization, enhanced data analytics, and AI integration.
Get Your Free Sample of The Global Rare Biomarkers Specimen Collection And Stabilization Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp
What key drivers have fueled the rare biomarkers specimen collection and stabilization market’s development over the years?
The increasing prevalence of cancer is expected to propel the growth of the rare biomarker specimen collection and stabilization market going forward. Cancer is a group of diseases defined by the uncontrolled proliferation and spread of abnormal cells. The prevalence of cancer is rising owing to environmental pollutants and lifestyle factors, such as smoking and poor diet choices, exacerbating genetic predispositions. The utilization of rare biomarker specimen collection and stabilization methods in cancer prevalence studies facilitates more accurate detection and monitoring of specific cancer types, enhancing diagnostic and therapeutic approaches. For instance, in October 2023, according to a report by the European Commission, a Europe-based governing body, new cancer cases rose to 2.74 million in 2022, indicating a 2.3% increase from 2020. Therefore, the increasing prevalence of cancer is driving the growth of the rare biomarker specimen collection and stabilization market.
What is the segmentation for the rare biomarkers specimen collection and stabilization market?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented –
1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum
Order your report now for swift delivery
Who are the most influential companies in the rare biomarkers specimen collection and stabilization market?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC
What are the top industry trends projected to impact the rare biomarkers specimen collection and stabilization market?
Major companies operating in the rare biomarker specimen collection and stabilization market are focusing on developing innovative solutions, such as a pre-analytical platform to automate the preparation of plasma and cell samples for multiomic liquid biopsy. Pre-analytical platform provides consistent, automated fresh sample preparation at the time of blood collection. It allows for complete walk-away processing of whole blood without the need for special tubes or skilled professionals, therefore preserving sample integrity. For instance, in May 2022, Tethis S.p.A., an Italy-based biotechnology company, launched See.d, the first fully automated, standardized pre-analytical platform that offers unique features such as precise sample handling, efficient separation of plasma for cellular fractions, and fixation of white blood cells on SmartBioSurface slides. The platform features a quality control scoring system for objectively evaluating sample stability. This approach enables the systematic scoring of proteomics and metabolomics data sets to determine the stability of plasma and serum samples.
What are the major regional insights for the rare biomarkers specimen collection and stabilization market, and which region holds the top position?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Rare Biomarkers Specimen Collection And Stabilization Market Report 2025 Offer?
The rare biomarkers specimen collection and stabilization market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Rare biomarkers specimen collection and stabilization refers to the process of collecting and preserving biological samples containing rare or low-abundance molecules that serve as indications of specific biological processes, diseases, or situations. These biomarkers could be specific proteins, nucleic acids, metabolites, or other substances. The aim of collecting and preserving rare biomarkers is to enable accurate and reliable measurement and analysis of these molecules for diagnostic, prognostic, and therapeutic applications.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15913
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
